Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China
CDMO, Regulators Play Catch-Up
Executive Summary
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.